Italy: Alfasigma consolidates position in Italy with Sofar acquisition

Privately owned, Alfasigma, an Italy based multinational pharmaceutical company, is to acquire the entire share capital of another Italian pharmaceutical company, Sofar. Both companies focus on the gastrointestinal area. Sofar carries out approximately 80% of its activity in this therapeutic area and has concentrated research on the microbiota within its laboratory located in Bergamo. Alfasigma is developing a…

You must be a HMI Subscriber to view this content.

Subscribe Now »